BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

BriaCell (BCTX) Therapeutics announces that it is presenting positive data in three clinical posters at the 2026 American Association for Cancer Research, AACR, Annual Meeting, taking place April 17-22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell’s ongoing Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, and two posters highlighting further analyses of Phase 2 data. Abstracts will be published in the online Proceedings of the AACR. “Standards of care in cancer are evolving rapidly as innovative immunotherapy approaches emerge with potentially better safety profiles than chemotherapy. Clinical data, including BriaCell’s, highlight that maintaining quality of life is an important treatment goal alongside efficacy and safety,” stated lead author, Saranya Chumsri, MD, Principal Investigator of BriaCell Phase 3 study of Bria-IMT+CPI, and Professor of Oncology, Mayo Clinic.